Anhui Wanbang Pharmaceutical Technology301520.SZValuation Analysis

As of Oct 19, 2026, Anhui Wanbang Pharmaceutical Technology (301520.SZ) trades at a P/E of 593.00x, P/B of 3.87x, P/S of 33.00x, and a dividend yield of 0.34%.
Longitudinal percentile comparison: P/E sits at the 94th percentile over the trailing 10Y window (vs. 94th percentile over 3Y); P/B sits at the 90th percentile over the trailing 10Y window (vs. 91st percentile over 3Y); P/S sits at the 90th percentile over the trailing 10Y window (vs. 89th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 99th percentile within its industry and the 98th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.56%, ranking at the 18th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 4.1 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 0.34% comes from cash dividends, with an implied ~0.21% from buybacks — a fairly balanced mix of both channels. Anhui Wanbang Pharmaceutical Technology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.